Among these targets, only ATP6V1A, DLL3, IKBKB, MEPCE, NOTCH1, NRF1, SFRP1, and SOX2 showed a consistent expression profile among gliomas, GBM, and LGG (Supplementary Table S3 and Supplementary Figure S2). This evidence concerns the gene DLL3 and central nervous system cancer.